Mirum Pharmaceuticals Inc To Acquire Travere Therapeutics Inc Call Transcript
Hello, and welcome to the Mirum Pharmaceuticals' business update. My name is [Elliot], and I will be coordinating your call today. (Operator Instructions) I'd now like to hand over to Andrew McKibben, Vice President of Investor Relations. The floor is yours. Please go ahead.
Thanks, [Elliot], and good morning, everyone. I'd like to welcome you to Mirum Pharmaceuticals conference call. I'm joined today by our President and CEO, Chris Peetz; our Chief Operating Officer, Peter Radovich; and our Head of R&D, Pam Vig. For our Q&A session, we are also joined by our Chief Development Officer, Lara Longpre.
Earlier today, Mirum issued a news release announcing its acquisition of Travere Therapeutics product portfolio of bile acid therapeutics for rare genetic pediatric diseases. This news release can be found in the Investors section of our website. Speakers will be referencing a transaction announcement presentation that can be found in the Events section of our website.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |